Cytomegalic Inclusion Disease Overview

Save information for later
Sign Up

Learn About Cytomegalic Inclusion Disease

What is the definition of Cytomegalic Inclusion Disease?
Cytomegalic inclusion disease is an infection in newborns caused by the cytomegalovirus. When a pregnant woman has an active cytomegalovirus infection during pregnancy or breastfeeding, the virus can be passed to their babies. Cytomegaloviruses are also known as salivary gland viruses.
What are the symptoms of Cytomegalic Inclusion Disease?
Symptoms of cytomegalic inclusion disease in the newborn can range from no symptoms to severe symptoms affecting the central nervous system, liver, spleen, and possibly causing developmental disabilities. Other symptoms of severe cytomegalic inclusion disease in infants may include hemorrhagic anemia, low birth weight, fever, hepatitis, yellowing of the skin and whites of the eyes, rash, purple skin blotches, pneumonia, enlarged liver and/or spleen, decreased blood platelets, eye inflammation, abnormally small head, calcification of the ventricles of the brain, developmental motor defects, cognitive disabilities, spastic paralysis, blindness, deafness, and seizures.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Cytomegalic Inclusion Disease?
There is currently no cure for cytomegalic inclusion disease. Treatment for cytomegalic inclusion disease is focused on controlling symptoms. Treatments for cytomegalic inclusion disease include antiviral drugs, such as gancicolovir and foscarnet; azathioprine; prednisone; basiliximab; and miconazole.
Who are the top Cytomegalic Inclusion Disease Local Doctors?
Mark R. Schleiss
Elite in Cytomegalic Inclusion Disease
Dr. Mark R. Schleiss
Pediatrics | Infectious Disease
Elite in Cytomegalic Inclusion Disease
Dr. Mark R. Schleiss
Pediatrics | Infectious Disease
516 Delaware Street Se, Pwb Fourth Floor, Room 4-100, 
Minneapolis, MN 
612-626-6777
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Schleiss is a Pediatrics specialist and an Infectious Disease provider in Minneapolis, Minnesota. Dr. Schleiss is rated as an Elite provider by MediFind in the treatment of Cytomegalic Inclusion Disease. His top areas of expertise are Congenital Cytomegalovirus, Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Sepsis, and Myringotomy. Dr. Schleiss is currently accepting new patients.

Michael J. Boeckh
Elite in Cytomegalic Inclusion Disease
Dr. Michael J. Boeckh
Infectious Disease
Elite in Cytomegalic Inclusion Disease
Dr. Michael J. Boeckh
Infectious Disease
1100 Fairview Ave N, 
Seattle, WA 
206-667-4898
Languages Spoken:
English, Castilian, German, Punjabi, Russian, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Boeckh is an Infectious Disease provider in Seattle, Washington. Dr. Boeckh is rated as an Elite provider by MediFind in the treatment of Cytomegalic Inclusion Disease. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Parainfluenza, and Shingles. Dr. Boeckh is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Paul H. Moss
Elite in Cytomegalic Inclusion Disease
Paul H. Moss
Elite in Cytomegalic Inclusion Disease
Paul H. Moss
Birmingham, ENG, GB 

Paul Moss practices in Birmingham, United Kingdom. Mr. Moss is rated as an Elite expert by MediFind in the treatment of Cytomegalic Inclusion Disease. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Pancreaticoduodenectomy.

View All Doctors
What are the latest Cytomegalic Inclusion Disease Clinical Trials?
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Who is this study for: Patients with Infection
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Drug: Virus-specific Cytotoxic T-lymphocytes
Study Phase: Phase 1

Summary: This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in immunocompromised patients with cancer. Viral infections are a leading cause of morbidity and mortality after hematopoietic stem cell transplantation, and therapeutic options f...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I Pharmacokinetic and Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Disease
A Phase I Pharmacokinetic and Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Disease
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects will receive one dose of oral letermovir (Study Day 0), using the dose bands. A full pharmacokinetics (...

View All Clinical Trials